Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
OMER

OMER - Omeros Corp Stock Price, Fair Value and News

4.24USD+0.47 (+12.47%)Market Closed

Market Summary

OMER
USD4.24+0.47
Market Closed
12.47%

OMER Stock Price

View Fullscreen

OMER RSI Chart

OMER Valuation

Market Cap

245.7M

Price/Earnings (Trailing)

-2.03

Price/Sales (Trailing)

16.14

EV/EBITDA

-2.47

Price/Free Cashflow

-1.73

OMER Price/Sales (Trailing)

OMER Profitability

EBT Margin

-1195.99%

Return on Equity

170.05%

Return on Assets

-27.73%

Free Cashflow Yield

-57.84%

OMER Fundamentals

OMER Revenue

Revenue (TTM)

15.2M

Rev. Growth (Yr)

-13.83%

Rev. Growth (Qtr)

-0.41%

OMER Earnings

Earnings (TTM)

-121.3M

Earnings Growth (Yr)

-10.34%

Earnings Growth (Qtr)

-310.06%

Breaking Down OMER Revenue

Last 7 days

-5.3%

Last 30 days

0.5%

Last 90 days

2.5%

Trailing 12 Months

-40.2%

How does OMER drawdown profile look like?

OMER Financial Health

Current Ratio

4.76

Debt/Equity

-1.85

Debt/Cashflow

-1.08

OMER Investor Care

Buy Backs (1Y)

7.77%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202415.2M000
20237.4M011.3M13.8M
20222.5M03.3M4.1M
202171.3M86.6M44.2M1.7M
2020113.6M100.3M96.6M73.8M
201950.1M75.2M100.4M111.8M
201856.1M47.3M38.6M29.9M
201746.5M53.6M64.0M64.8M
201620.4M27.2M35.2M41.4M
2015827.0K4.0M7.0M13.5M
2014605.0K510.0K528.0K539.0K
20135.6M4.2M3.0M1.6M
20124.8M5.2M5.6M6.0M
20113.0M3.6M4.4M4.5M
201001.7M1.9M2.1M
20090001.4M

Tracking the Latest Insider Buys and Sells of Omeros Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 17, 2023
demopulos gregory a md
bought
25,200
1.68
15,000
chairman, ceo & president
Nov 15, 2023
demopulos peter a md
bought
15,300
1.53
10,000
-
Nov 14, 2023
demopulos gregory a md
acquired
36,000
1.44
25,000
chairman, ceo & president
Nov 13, 2023
demopulos gregory a md
acquired
48,375
1.29
37,500
chairman, ceo & president
Sep 12, 2023
bumol thomas f.
acquired
33,100
3.31
10,000
-
May 22, 2023
hanish arnold c
sold
-32,300
6.46
-5,000
-
May 22, 2023
hanish arnold c
acquired
26,500
5.3
5,000
-
May 22, 2023
cable thomas j.
sold
-32,650
6.53
-5,000
-
May 22, 2023
cable thomas j.
acquired
26,500
5.3
5,000
-
Sep 08, 2021
hanish arnold c
acquired
94,400
9.44
10,000
-

1–10 of 43

Which funds bought or sold OMER recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
reduced
-65.29
-60,000
35,000
-%
May 16, 2024
COMERICA BANK
added
20.00
21,750
103,500
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
added
6.95
-2,113
44,910
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.91
-11,648
21,117
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-80.28
-170,850
44,888
-%
May 16, 2024
Ancora Advisors LLC
reduced
-27.29
-124,143
408,942
0.01%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-13.42
-52,716
556,485
0.01%
May 15, 2024
HSBC HOLDINGS PLC
new
-
50,798
50,798
-%
May 15, 2024
STATE STREET CORP
added
2.99
340,118
4,267,150
-%
May 15, 2024
Sculptor Capital LP
new
-
331,200
331,200
0.01%

1–10 of 39

Are Funds Buying or Selling OMER?

Are funds buying OMER calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OMER
No. of Funds

Unveiling Omeros Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 27, 2024
ingalls & snyder llc
7.0%
4,431,188
SC 13G/A
Feb 14, 2024
demopulos gregory a md
8.80%
5,704,061
SC 13G/A
Feb 13, 2024
vanguard group inc
5.04%
3,168,936
SC 13G
Jan 29, 2024
blackrock inc.
6.8%
4,279,836
SC 13G
Feb 17, 2023
ingalls & snyder llc
6.6%
4,131,793
SC 13G/A
Feb 14, 2023
demopulos gregory a md
8.37%
5,551,980
SC 13G/A
Feb 09, 2023
vanguard group inc
4.50%
2,820,445
SC 13G/A
Jul 08, 2022
blackrock inc.
2.0%
1,225,787
SC 13G
Feb 14, 2022
demopulos gregory a md
8.07%
5,314,624
SC 13G/A
Feb 14, 2022
cormorant asset management, lp
0%
0
SC 13G/A

Recent SEC filings of Omeros Corp

View All Filings
Date Filed Form Type Document
Jun 12, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report
May 15, 2024
10-Q
Quarterly Report

Peers (Alternatives to Omeros Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
17.55% 15.42%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
6.10% -19.49%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.03% -10.77%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
4.06% -3.24%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
16.82% -26.89%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
20.98% 97.26%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
19.55% 492.49%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-16.55% 51.92%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Omeros Corp News

Latest updates
Defense World09 Jun 202404:27 pm
Yahoo New Zealand News07 Jun 202406:36 pm
Yahoo Finance15 May 202407:00 am

Omeros Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-0.4%3,415,0003,429,0004,413,0003,963,0001,993,000906,000493,0009,936,33319,379,66728,823,00021,061,00010,632,00026,114,00013,530,00023,537,00033,417,00029,856,00026,753,00021,779,00022,017,0004,608,000
Costs and Expenses-1.8%39,034,00039,765,00048,153,00035,713,00040,138,50050,766,00035,046,00042,889,00039,828,00045,610,00045,290,00044,448,00051,542,00041,210,00047,214,00057,121,00040,957,00036,091,00041,018,00040,491,00040,050,000
Operating Expenses-------------------41,018,00040,491,00040,050,000
  S&GA Expenses12.8%12,264,00010,875,00016,422,00011,103,00013,589,00012,198,00010,959,00012,562,00014,010,00015,484,00012,786,000-5,486,00019,825,00016,931,00018,036,000-8,779,00016,933,00016,928,00014,632,00014,888,00013,152,000
  R&D Expenses-7.3%26,770,00028,890,00031,731,00024,610,00026,549,50038,568,00024,087,00030,327,00025,818,00030,126,00032,504,00023,253,00031,316,00024,132,00028,911,00037,215,50023,746,00019,108,00026,255,00025,446,00026,862,000
EBITDA Margin9.5%-9.85-10.89-13.26-21.14-38.99-73.32-95.83-138-5.53-2.73-----------
Interest Expenses16.5%8,231,0007,063,0007,916,0007,933,0007,902,5004,932,0004,941,0004,951,0004,911,0004,910,0004,897,0007,988,0006,882,0005,978,0005,903,0005,811,5005,715,0005,530,0005,600,0005,148,5004,602,000
Income Taxes-------------15,402,000-7,854,000--------
Earnings Before Taxes---------105,160,000-22,703,000---87,747,000-46,317,000---111,881,000-16,463,000----
EBT Margin9.3%-11.96-13.19-16.14-24.75-44.81-79.66-104-150-6.08-3.03-----------
Net Income-310.1%-37,184,000-9,068,000-37,750,000-33,701,000128,733,000-17,456,000-33,011,000280,621,000-22,703,000-28,593,000-35,090,000-37,273,000-38,463,000-33,294,000-29,031,000-29,225,000-16,463,000-14,453,000-24,345,000-23,534,000-39,472,000
Net Income Margin6.7%-7.97-8.541.776.3511.6760.6278.09111-2.80-1.61-----------
Free Cashflow-19.5%-41,838,000-35,018,000-32,631,000174,539,000-25,395,000-26,436,000-15,267,000-18,289,000-23,764,000-27,680,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets15.7%43737849352756059145834636941912314516118122771.0011813791.0090.00101
  Current Assets28.9%28121835138941744328919321024891.0011213215119639.0086.0010464.0066.0077.00
    Cash Equivalents-74.2%2.007.0031.007.004.0011.0014614.009.001017.0013.009.0011.0021.002.007.003.009.004.004.00
  Inventory-----------1.001.001.001.002.002.001.001.001.001.001.00
  Net PPE-7.5%2.002.002.00--1.00--------3.003.003.004.004.004.004.00
  Current Liabilities10.8%59.0053.0014714413913640.0039.0035.0052.0043.0048.0043.0037.0048.0038.0058.0055.0047.0041.0045.00
    LT Debt, Current---------------------3.00
Shareholder's Equity-185.5%-71.33-24.98-21.0055.0086.00---24.00-----------
  Retained Earnings-4.9%-790-753-744-706-669-635-764-746-716-683-963-941-912-872-835-796-763-734-705-688-674
  Additional Paid-In Capital-1.3%719728730727724721718714711706700694690751747635631625565558553
Shares Outstanding-5.2%58.0061.0063.0063.0063.0063.0063.0063.0063.0062.0063.0062.00---------
Float----328---166---887---762---729-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-19.7%-41,780-34,900-32,600-32,339174,539-25,382-26,439-19,469-15,193-18,215-23,661-27,592-40,254-18,407-34,941-37,597-9,141-23,014-7,522-16,589-12,948
  Share Based Compensation-1.2%2,6582,6913,2352,7712,9533,2643,8443,0723,8925,5485,6943,1173,2713,8033,8243,8223,4763,3173,4963,5983,374
Cashflow From Investing-153.3%-61,925116,24357,16735,375-181,331-108,49132,99924,741-76,813112,41817,89630,41132,9857,996-118,39732,59410,776-39,2399,33915,21211,287
Cashflow From Financing193.8%98,431-104,953-483-260-388-651124,837-99.00161-8104788555,796-163172,449-1512,39956,4763,0581,309-146
  Buy Backs-11,851--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OMER Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Costs and expenses:  
Research and development$ 26,770$ 24,610
Selling, general and administrative12,26411,103
Total costs and expenses39,03435,713
Loss from operations(39,034)(35,713)
Interest expense(8,231)(7,933)
Interest and other income3,4153,963
Net loss from continuing operations(43,850)(39,683)
Net income from discontinued operations, net of tax6,6665,982
Net loss$ (37,184)$ (33,701)
Basic and diluted net income (loss) per share:  
Net loss from continuing operations (in dollars per share)$ (0.75)$ (0.63)
Net income from discontinued operations (in dollars per share)0.120.09
Net loss (in dollars per share)$ (0.63)$ (0.54)
Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares)58,800,71662,828,765

OMER Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 1,831$ 7,105
Short-term investments228,503164,743
OMIDRIA contract royalty asset, short-term29,51929,373
Receivables7,6428,096
Prepaid expense and other assets13,4638,581
Total current assets280,958217,898
OMIDRIA contract royalty asset135,909138,736
Right of use assets17,76718,631
Property and equipment, net1,8041,950
Restricted investments1,0541,054
Total assets437,492378,269
Current liabilities:  
Accounts payable6,1827,712
Accrued expenses28,40231,868
Current portion of OMIDRIA royalty obligation19,1308,576
Current portion of lease liabilities5,3425,160
Total current liabilities59,05653,316
Convertible senior notes, net213,463213,155
OMIDRIA royalty obligation, non-current217,459116,550
Lease liabilities, non-current16,75418,143
Other accrued liabilities, non-current2,0882,088
Commitments and contingencies (Note 10)
Shareholders’ equity (deficit):  
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023.00
Common stock, par value $0.01 per share, 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 57,942,695 and 61,128,597 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.579611
Additional paid-in capital718,807727,936
Accumulated deficit(790,714)(753,530)
Total shareholders’ deficit(71,328)(24,983)
Total liabilities and shareholders’ equity (deficit)$ 437,492$ 378,269
OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEomeros.com
 INDUSTRYBiotechnology
 EMPLOYEES196

Omeros Corp Frequently Asked Questions


What is the ticker symbol for Omeros Corp? What does OMER stand for in stocks?

OMER is the stock ticker symbol of Omeros Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omeros Corp (OMER)?

As of Wed Jun 12 2024, market cap of Omeros Corp is 218.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers.

What is the fair value of OMER stock?

You can check OMER's fair value in chart for subscribers. The fair value of Omeros Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omeros Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMER so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omeros Corp a good stock to buy?

The fair value guage provides a quick view whether OMER is over valued or under valued. Whether Omeros Corp is cheap or expensive depends on the assumptions which impact Omeros Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMER.

What is Omeros Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, OMER's PE ratio (Price to Earnings) is -1.8 and Price to Sales (PS) ratio is 14.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMER PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omeros Corp's stock?

In the past 10 years, Omeros Corp has provided -0.124 (multiply by 100 for percentage) rate of return.